Daiichi Sankyo Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DAIICHI SANKYO
DAIICHI SANKYO has three approved drugs.
There are twenty-five US patents protecting DAIICHI SANKYO drugs.
There are three hundred and thirty-four patent family members on DAIICHI SANKYO drugs in forty-seven countries and thirty supplementary protection certificates in eighteen countries.
Summary for Daiichi Sankyo
| International Patents: | 334 |
| US Patents: | 25 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
| Patent Litigation for Daiichi Sankyo: | See patent lawsuits for Daiichi Sankyo |
| PTAB Cases with Daiichi Sankyo as patent owner: | See PTAB cases with Daiichi Sankyo as patent owner |
Drugs and US Patents for Daiichi Sankyo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 7,820,657 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-002 | Oct 14, 2022 | RX | Yes | Yes | 8,722,702 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 8,865,710 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-002 | Oct 14, 2022 | RX | Yes | Yes | 10,730,876 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-001 | Jan 8, 2015 | RX | Yes | No | 7,365,205 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for DAIICHI SANKYO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
International Patents for Daiichi Sankyo Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 2140867 | ⤷ Start Trial |
| Malaysia | 149356 | ⤷ Start Trial |
| European Patent Office | 2001892 | ⤷ Start Trial |
| South Korea | 20180015142 | ⤷ Start Trial |
| Taiwan | I660956 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Daiichi Sankyo Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1405852 | 1590052-5 | Sweden | ⤷ Start Trial | PRODUCT NAME: EDOXABAN, A SALT THEREOF, A SOLVATE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE.; REG. NO/DATE: EU/1/15/993/001-028 20150623 |
| 1405852 | 122015000077 | Germany | ⤷ Start Trial | PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
| 2429524 | C20240009 | Finland | ⤷ Start Trial | |
| 2140867 | PA2018005,C2140867 | Lithuania | ⤷ Start Trial | PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
| 2429524 | LUC00338 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: QUIZARTINIB; AUTHORISATION NUMBER AND DATE: EU/1/23/1768 20231107 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
